Accro Bioscience
Suzhou, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $50M
Overview
Clinical-stage biotech developing novel therapeutics targeting regulated cell death mechanisms for immune-mediated diseases and cancer.
OncologyImmunology
Technology Platform
A proprietary 'Regulated Cell Death' drug discovery platform focused on the 'Cell Death-Inflammation' loop, enabling the identification of novel targets in pathways like necroptosis and pyroptosis for therapeutic intervention.
Funding History
1Total raised:$50M
Series C$50M
Opportunities
Significant opportunity lies in demonstrating proof-of-concept for its RCD platform across multiple clinical programs, potentially leading to lucrative global partnerships for AC-201 in autoimmune diseases and expanding into oncology indications where RCD plays a key role.
Risk Factors
Key risks include clinical failure of lead assets in larger trials, intense competition in the JAK/TYK2 and RIPK inhibitor spaces, and reliance on partnership funding and terms for further development and commercialization.
Competitive Landscape
Faces competition from other biopharma companies developing RIPK1 inhibitors (e.g., Denali, Roche) and TYK2 inhibitors (e.g., Bristol Myers Squibb); differentiation is based on its specialized RCD platform and a pipeline targeting multiple nodes within this pathway.